Introduction {#s1}
============

Last decades, a significant reduction of the number of patients infected with hepatitis C virus (HCV) has been observed in the hemodialysis units. However, hemodialysis patients have higher incidence of HCV infection compared to the general population. Despite the relatively mild clinical course of the disease, HCV infection is an independent and significant risk factor of the increased mortality in these patients \[[@R01]-[@R05]\]. [Introduction](#s1){ref-type="sec"} of direct-acting antiviral agents (DAAs) into clinical practice allowed achieving high efficacy among various groups of HCV-infected patients, including those with liver cirrhosis. As all patients in dialysis units are regularly screened and evaluated for HCV infection, there is a realistic opportunity of HCV elimination in this group. However, there are a number of limitations which make this goal difficult to achieve. Until recent time, SOF-containing regimens were the only option to treat chronic HCV infection genotypes (Gt) 2 and 3, but they cannot be used in patients on hemodialysis. Moreover, so-called HCV recombinant Gt, in particular 2k/1b variant, proved to be resistant not only to interferon therapy, but also to some DAAs \[[@R06]\].

A new pan-genotypic DAA combination, gleсaprevir/pibrentasvir (GLE/PIB) with an extra-renal elimination, with proven efficacy in hemodialysis patients, is a promising option for this group \[[@R07]\]. However, it has not been studied in patients infected with 2k/1b HCV variant.

The purpose of our report is to provide information on the first experience of using GLE/PIB combination in a hemodialysis patient infected with the chimeric HCV Gt 2k/1b.

Case Report {#s2}
===========

A 57-year-old Caucasian man had an elevated blood pressure of 200/100 mm Hg and an increased serum creatinine (exact value is unknown) during routine outpatient check-up in 2006. After abdominal and kidney ultrasound, he was referred to nephrologist and diagnosed with autosomal-dominant polycystic kidney disease (ADPKD) with liver involvement. Family history was taken with no clear information about parents, but it was found that the patient's elder son was diagnosed with ADPKD, while the younger son never underwent examination for ADPKD.

In 2011, serum creatinine was already 364 µmol/L, hemoglobin (Hb) was 124 g/L, bilirubin, aspartate transaminase (AST) and alanine transaminase (ALT) were all within normal range ([Fig. 1](#F1){ref-type="fig"}). By April 2012, his creatinine increased to 916 µmol/L, and estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 8 mL/min/1.73 m^2^ \[[@R08]\]. In September 2012, patient was started on hemodialysis. Hepatitis B surface antigen (HBsAg) and anti-HCV were undetectable. In April 2013, bilateral nephrectomy was performed in preparation to kidney transplantation. In February 2014, his aminotransferases were found three times increasing upper normal limit, and antibodies to the HCV were detected. Gamma-glutamyltranspeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin were within normal ranges. By July 2014, AST and ALT decreased to 36 and 60 U/L, respectively. He underwent kidney transplantation, complicated by bleeding in the early postoperative period, and in August 2014, a transplantectomy was performed due to severe graft dysfunction. Hemodialysis treatment was resumed; patient received antihypertensive drugs (amlodipine and losartan) and erythropoietin on the regular basis.

![The first information about effective and safe treatment with glecaprevir/pibrentasvir combination of rare HCV recombinant 2k/1b genotype in hemodialysis patient. ADPKD: autosomal-dominant polycystic kidney disease; HD: hemodialysis; KT: kidney transplantation; SVR: sustained virologic response; BP: blood pressure; Сr: creatinine; TE: transient elastography; N: normal range.](gr-12-176-g001){#F1}

During next 3 years, only slight increase of ALT was observed. In 2017, Gt 2 of HCV (further 2k/1b variant) was identified. The viral load was 7.1 × 10^4^ IU/mL. Other laboratory findings included Hb 121 g/L, white blood cell count (WBC) 3.7 × 10^9^/L, platelets (PLT) 96 × 10^9^/L, total protein 77 g/L, albumin 40 g/L, total bilirubin 10.1 µmol/L, AST 20 U/L, ALT 52 U/L, GGT 47 U/L, ALP 80 U/L, creatinine 838 µmol/L, alpha-fetoprotein 6.0 U/mL and international normalized ratio (INR) 1.04.

Abdomen ultrasound showed hepatosplenomegaly, increased liver echogenicity with well-preserved vascular pattern, heterogeneous echo-structure with multiple cysts up to 25 mm in diameter ([Fig. 2](#F2){ref-type="fig"}). Diameter of the hepatic vein was 9.5 mm and the spleen vein was 6 mm. The results of transient elastography (TE) were not fully reliable due to cystic liver disease; however, the reason for such a rapid increase of the hepatic parenchyma density (from 10.1 to 24.6 kPa) within a few months remained unclear.

![The ultrasound scan showed multiple cysts in the liver.](gr-12-176-g002){#F2}

Antiviral therapy was not initiated that time due to contraindications for SOF-containing regimens.

On December 14, 2017, antiviral treatment using new pan-genotypic combination of glecaprevir and pibrentasvir (GLE/PIB, 300/120 mg/day) was initiated in frame of the pre-approval access program. Tolerability of therapy was satisfactory, and the patient noted only slight intensification of his skin itching. Four weeks after the start of therapy, aviremia was achieved, and persisted until the end of treatment. After 12 weeks of therapy, HCV elimination was confirmed, that is, SVR12 was achieved.

Discussion {#s3}
==========

Uses of so-called universal methods for the prevention of HCV infection lead to a significant reduction of the HCV-infection incidence in the dialysis units in developed countries last decades. In Russia, according to the National Registry, average proportion of HCV-antibodies carriers among hemodialysis patients is 11.6%, with a significant variability ranging from 1-4% to 25-50%, depending on the socio-economic development of the region \[[@R9]\].

The negative effect of chronic HCV infection on the prognosis of patients receiving renal replacement therapy (hemodialysis and kidney transplantation) has been convincingly proved. Therefore, the introduction DAAs with high efficacy and safety opened new opportunities for treatment of these patients. Excellent results of the combination of paritaprevir/ritonavir with ombitasvir and dasabuvir ("3D") usage in HCV-infected hemodialysis patients with Gt 1 and 4 were shown. Abad et al and Ponziani et al reported 100% SVR12 in hemodialysis patients. It should be emphasized that the last study included only patients with liver cirrhosis and those who did not respond to previous interferon-containing therapy \[[@R10], [@R11]\]. No cases of early termination of treatment due to adverse events were reported.

Treatment of chronic HCV infection Gt 2 and 3 with SOF-containing regimens in hemodialysis patients was allowed only in selected cases, as SOF is contraindicated for patients with eGFR \< 30 mL/min \[[@R12]\].

A new pan-genotypic combination of DAAs, GLE/PIB with the minimal level of renal excretion, showed its high efficiency in hemodialysis patients with chronic hepatitis C, including those with liver cirrhosis. In the EXPEDITION-4 study, 104 patients with impaired renal function (stage 4 and stage 5 of chronic kidney disease) were enrolled. Eighty-five of subjects received hemodialysis, and 28 of them were infected by HCV Gt 2 or 3 \[[@R07]\]. In 20 patients, compensated liver cirrhosis was diagnosed. SVR12 in this group was achieved by 98% of patients after the 12-week course of treatment. Serious adverse events associated with the use of this combination of drugs were not registered. In another study, all of 12 patients with severe renal dysfunction achieved SVR12 \[[@R13]\]. In this group, nine patients were infected with HCV Gt 2, four received hemodialysis and two had compensated liver cirrhosis. It is important to emphasize that patients without liver cirrhosis received antiviral therapy for 8 weeks, and the group of cirrhotic patients received antiviral therapy for 12 weeks.

We observed seven hemodialysis patients infected with HCV Gt 2 and 3, receiving GLE/PIB therapy. SVR12 was 100% (unpublished data). One of them was infected with 2k/1b variant of the HCV.

The 2k/1b chimeras were first detected in blood samples from patients with chronic HCV infection in St. Petersburg (Russia) by Kalinina et al in 2002 \[[@R14]\]. Presumably this recombinant genotype emerged in Russia (Soviet Union those times) between 1923 and 1956 \[[@R15]\]. Recombination resulted from the high frequency of mutation of the virus and led to the formation of genetic diversity of HCV. HCV 2k/1b variant appeared to be more viable than others detected HCV chimeras (2i/6p, 2b/1b, 2/5, 2b/6w, 2b/1a and 2a/1b). The frequency of its detection in St. Petersburg region reaches 7.5% of the total number of infected patients, and 6.3% of infected hemodialysis patients in this city \[[@R16]\]. In general, the prevalence of recombinant 2k/1b virus in Russia is 4% among all HCV-infected patients, and 40% among those infected with Gt 2 \[[@R17]\]. There is a significant variability in infection rate with this recombinant variant in the former Soviet republics. For example, in Georgia, prevalence of 2k/1b variant among all patients with chronic HCV infection reaches 19.7-22.2%, and 72-76% among patients with Gt 2, while in Uzbekistan, prevalence of 2k/1b variant does not exceed 1% of the total infected population \[[@R18]-[@R20]\].

An interesting study, conducted by German group, showed high incidence of recombinant HCV 2k/1b strains in patients infected with HCV Gt 2 in Germany (13%), and especially in Israel (25%), countries with the high proportion of emigrants from the former Soviet Union, and vice versa, the absence of recombinant variants in Italy, where the number of such emigrants is much lower \[[@R06]\]. More international studies are needed to address the prevalence of 2k/1b variant in other countries with a significant number of emigrants from the Soviet Union and countries of the post-Soviet space.

HCV Gt 1b is most prevalent type of virus in Russia, in particular in Moscow hemodialysis units. At the same time, HCV Gt 2 is a rare. However, the high prevalence of the 2k/1b chimera among Gt 2 HCV is a reason for clinical concerns about infection with this recombinant variant of the HCV. Taking into consideration this possibility, the deep sequencing analysis of HCV geno-/subtype was performed in our patient and the 2k/1b was identified.

The unique feature of our patient was the combination of chronic HCV infection with liver cysts in frame of autosomal-dominant polycystic kidney disease. This disease is typically complicated by severe kidney damage, which, like in our case, often leads to the end stage of kidney disease, requiring renal replacement therapy. Clinical activity of chronic hepatitis C was low, which is typical for hemodialysis patients; according to different authors, ALT in these patients usually does not exceed 18 or 27 U/L \[[@R21], [@R22]\].

Absence of correlation between aminotransferases levels and disease activity in hemodialysis patients complicates assessment of disease severity. It is well known that liver biopsy is the optimal method for diagnostics of inflammatory activity and fibrosis stage \[[@R23]\]. However, the high risk of complications, especially bleeding, in dialysis patients, increases the value of non-invasive methods. Liver TE usage in patients receiving hemodialysis was evaluated by Liu et al, 2011 \[[@R24]\]. The authors showed that it is more informative than the AST to platelet ratio index (APRI). However, the lack of information on the correlation of data obtained with TE and liver biopsy in hemodialysis patients, as well as the possible effect of liquid overload in the interdialysis period on the results of the examination, requires more evidence to prove the adequacy of replacing liver biopsy with TE \[[@R25]\]. Presence of multiple cysts additionally influenced the reliability of TE results in our patient.

Evaluation of DAAs efficacy in patients with HCV Gt 2k/1b is currently under investigation. It was shown that the combination of SOF/ribavirin demonstrated good results in patients infected with HCV Gt 2, but had poor efficacy in subjects infected with recombinant variant \[[@R26]\]. In contrast, the usage of pan-genotypic DAAs' combinations (SOF/daclatasvir and SOF/velpatasvir), as well as combinations recommended for treatment of HCV Gt 1 (SOF/ledipasvir, "3D" therapy) showed good results as initial treatment in patients with HCV variant 2k/1b (n - 9), as well as in cases of unsuccessful previous treatment with SOF/ribavirin (n - 13). SVR12 was achieved in 21 of 22 patients (95.5%) \[[@R06]\]. It should be noted that 15 out of these 22 patients received treatment with SOF-containing regimens and seven received "3D" therapy.

We could not use SOF-containing regimens in our patient due to very low GFR. Taking into account German experience, we preferred to use the pan-genotypic combination GLE/PIB in frame of the pre-approval access program in Russia. We could not reliably estimate the severity of liver fibrosis, because the TE results could be greatly distorted by the presence of numerous cysts. Aminotransferases were just moderately elevated, especially taking into account normal values for hemodialysis patients. However, splenomegaly, leukopenia and thrombocytopenia indicated high probability of progressive liver fibrosis, despite a relatively short time from the hit of HCV infection. On this basis, it was decided to initiate a 12-week course of antiviral therapy. Aviremia was reached by the fourth week of treatment, and SVR12 was achieved, despite severe comorbidity in our patient.

Conclusions {#s3a}
-----------

In our experience, the combination of GLE/PIB used for 12 weeks for treatment of HCV GT 2k/1b variant in a patient on hemodialysis proved to be effective, well tolerated and safe. The number of patients in European and American hemodialysis units infected with this variant of the virus is still unknown, however, may be substantial due to migration. Therefore, studies for evaluation of hepatitis C chimeric genotypes prevalence will help to identify patients population which may benefit from pan-genomic DAAs administration.
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